fda compounded semaglutide ends shortage, closing the door on Wegovy, Ozempic FDA Warns About Compounded Versions

Deb Crowell Brooke is incredibly informed and well-educated when it comes to interpreting and connecting the dots from Vibrant test data

In March 2024, Regor Therapeutics Group, a clinical-stage global biopharmaceutical company utilizing a cutting-edge drug discovery engine and a differentiated clinical development pipeline, announced the initiation of its Phase 2 trial of the highly selective oral GLP-1 agonist RGT-075

It triggers pituitary GH release without significant cortisol, prolactin, or aldosterone elevation

However, these findings cannot be extrapolated to transdermal delivery without specific evidence demonstrating equivalent bioavailability and pharmacokinetics

The water maze consisted of a circular tank painted black (diameter: 1 .6 m